Contents of this article
The immune system depends on peptides as signals, regulators, and effectors. From antimicrobial peptides that form the first line of defense against pathogens to peptide-based vaccines and immunotherapies that are reshaping cancer and infectious disease care, short amino acid chains remain vital to immune regulation. Recent advances in peptide biology and drug design are accelerating their translation into therapies that modulate immunity with precision.
Peptides in innate immunity
Antimicrobial Peptides
Antimicrobial peptides (AMPs) such as defensins and cathelicidins are secreted by epithelial cells and immune cells as part of the body’s first defense. These peptides can disrupt microbial membranes, neutralize endotoxins, and even modulate immune responses. Their broad-spectrum activity has inspired development of AMP-based therapeutics against resistant bacteria and viruses.
Pattern recognition and modulation
AMPs also influence the activity of dendritic cells, macrophages, and neutrophils. For example, LL-37 not only kills microbes but also modulates cytokine release, linking innate responses to adaptive immunity.
Cytokines and chemokines
Many cytokines are peptides or small proteins that orchestrate adaptive immunity. Interleukins, interferons, and chemokines regulate T cell differentiation, B cell activation, and the migration of immune cells. These peptide signals ensure targeted and proportional responses to infection or injury.
Thymic Peptides
Peptides also play roles in T cell education. Thymosin-α1, a peptide hormone from the thymus, enhances T cell maturation and is used clinically to modulate immunity in viral infections and some cancers.
Peptide vaccines and immunotherapy
Peptide vaccines
Peptide-based vaccines use synthetic epitopes, short amino acid sequences derived from pathogens or tumors, to stimulate immune responses. Unlike whole-protein vaccines, peptide vaccines are particular, safer, and easier to manufacture. Recent trials in COVID-19 peptide vaccines and cancer peptide vaccines highlight their potential.
Cancer immunotherapy
Peptides play a central role in immunotherapy, particularly in the design of neoantigen-based vaccines and the combination of checkpoint inhibitors. Personalized peptide vaccines that target tumor-specific mutations have shown promising immune activation in early-phase trials.
Peptides as immune modulators
Checkpoint regulation
Peptide mimetics are being developed to block or mimic immune checkpoints like PD-1/PD-L1 or CTLA-4, potentially offering oral or less immunogenic alternatives to monoclonal antibodies.
Autoimmunity
Synthetic peptides that induce immune tolerance are being tested for autoimmune diseases such as multiple sclerosis and type 1 diabetes. By selectively tolerizing T cells to autoantigens, these therapies aim to control autoimmunity without broad immunosuppression.
Advances in Peptide delivery for the immune system
Delivery remains a major challenge for peptide-based immunotherapies.
- Nanoparticle carriers and liposomes are improving peptide vaccine stability and uptake by antigen-presenting cells.
- Depot formulations allow slow release of immunogenic peptides, mimicking natural exposure and enhancing immune memory.
- Conjugation to TLR agonists or adjuvants enhances immunogenicity, overcoming the inherently low immunogenicity of short peptides.
Safety, tolerability, and challenges
While peptide therapies are generally safe, they face limitations:
- Short half-life without chemical modifications or carriers
- HLA restriction in peptide vaccines, requiring personalization for effective presentation
- Immune tolerance risks if peptides are degraded too rapidly or fail to stimulate sufficient responses
Despite these challenges, clinical trial data for peptide-based cancer vaccines, antimicrobial peptides, and immune modulators remain encouraging.
The next generation of immune-related peptide therapeutics will likely include:
- Personalized peptide vaccines tailored to patient-specific neoantigens
- Peptide checkpoint inhibitors as cost-effective alternatives to antibodies
- Engineered antimicrobial peptides with enhanced stability against resistant pathogens
- Orally available immunomodulatory peptides, leveraging novel absorption enhancers and carrier systems
Peptides serve as both the language of the immune system and the foundation of innovative therapies. With advances in design and delivery, peptide-based immunotherapies may soon become mainstream in infectious disease, oncology, and autoimmune care.
Research sources:
Antimicrobial peptides: mechanism of action, activity and clinical potential
Qi-Yu Zhang, Zhi-Bin Yan, Yue-Ming Meng, Xiang-Yu Hong, Gang Shao, Jun-Jie Ma, Xu-Rui Cheng, Jun Liu, Jian Kang and Cai-Yun Fu. Published in Military Medical Research 2021 | DOI: 10.1186/s40779-021-00343-2
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
Da-Wei Wu, Shuo-Peng Jia, Shu-Jun Xing, Hai-lan Ma, Xin Wang, Qi-Yu Tang, Zi-Wei Li, Qing Wu, Min Bai, Xin-Yong Zhang, Xiao-Feng Fu, Ming-Ming Jia, Yu Tang, Li Chen and Ning Li. Published in Springer Nature Clinical and Experimental Medicine 2024 | DOI: 10.1007/s10238-024-01436-7
Antimicrobial peptides´ immune modulation role in intracellular bacterial infection
Diana Ivonne Duarte-Mata and César Salinas-Carmona. Published in Frontier in Immunology 2023 | DOI: 10.3389/fimmu.2023.1119574
Cathelicidins – a rich seam of antimicrobial peptides waiting for exploitation
Alessandro Tossi, Marco Gerdol, Andrea Caporale, Sabrina Pacor, Mario Mardirossian, Marco Scocchi, Michael D. Prickett, Giorgio Manzini and Renato Gennaro. Published in Frontier in Drug Discovery 2024 | DOI: 10.3389/fddsv.2024.1458057
Review of Thymic Peptides and Hormones: From Their Properties to Clinical Application
Monika Besman, Aleksandra Zambrowicz and Magdalena Matwiejczyk. Published in Springer Nature International Journal of Peptide Research and Therapeutics 2024 | DOI: 10.1007/s10989-024-10666-y
Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?
Johan Svenson, Natalia Molchanova and Christina I. Schroeder. Published in Frontier in Immunology 2022 | DOI: 10.3389/fimmu.2022.915368
Francesco Scavello, Naji Kharouf, Philippe Lavalle, Youssef Haikel, Francis Schneider and Marie-Hélène Metz-Boutigue. Published in Frontier in Immunology 2022 | DOI: 10.3389/fimmu.2022.977175
A Reappraisal of Thymosin Alpha1 in Cancer Therapy